Targeted Pulse Quiz: August 4

Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR Exon 20–Mutant NSCLC.

Digital biopsy data show CAN-2409 plus radiation boosts durable lymphocyte-tumor engagement in localized prostate cancer, hinting at stronger immune surveillance and better control.

Adding subcutaneous epcoritamab to R-CHOP significantly improves progression-free survival in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.

Sarah Premji, MD, of Sarah Cannon Research Institute discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.

The ADC rinatabart sesutecan showed efficacy regardless of FRα status in heavily pretreated platinum-resistant ovarian cancer with a tolerable safety profile.

A cisplatin patch achieves 95.5% complete responses in early oral lesions, helping patients avoid surgery with durable control and minimal systemic toxicity.

The RASolute 309 trial is investigating frontline daraxonrasib plus the RAS G12D inhibitor zoldonrasib vs chemotherapy in advanced pancreatic ductal adenocarcinoma.

Ohio Medicaid patients with breast cancer often miss genomic tests; use stays under 40%, with stage, race, and long-term care status driving disparities.